» Articles » PMID: 24673373

Cancer Cell Membrane-coated Nanoparticles for Anticancer Vaccination and Drug Delivery

Overview
Journal Nano Lett
Specialty Biotechnology
Date 2014 Mar 29
PMID 24673373
Citations 458
Authors
Affiliations
Soon will be listed here.
Abstract

Cell-derived nanoparticles have been garnering increased attention due to their ability to mimic many of the natural properties displayed by their source cells. This top-down engineering approach can be applied toward the development of novel therapeutic strategies owing to the unique interactions enabled through the retention of complex antigenic information. Herein, we report on the biological functionalization of polymeric nanoparticles with a layer of membrane coating derived from cancer cells. The resulting core-shell nanostructures, which carry the full array of cancer cell membrane antigens, offer a robust platform with applicability toward multiple modes of anticancer therapy. We demonstrate that by coupling the particles with an immunological adjuvant, the resulting formulation can be used to promote a tumor-specific immune response for use in vaccine applications. Moreover, we show that by taking advantage of the inherent homotypic binding phenomenon frequently observed among tumor cells the membrane functionalization allows for a unique cancer targeting strategy that can be utilized for drug delivery applications.

Citing Articles

Harnessing the power of traceable system C-GAP: homologous-targeting to fire up T-cell immune responses with low-dose irradiation.

Zhuang W, Pan K, Wu J, Liu L, Lv S, Hu J J Nanobiotechnology. 2025; 23(1):207.

PMID: 40075499 PMC: 11905511. DOI: 10.1186/s12951-025-03281-6.


Leveraging nature's nanocarriers: Translating insights from extracellular vesicles to biomimetic synthetic vesicles for biomedical applications.

Chen Y, Douanne N, Wu T, Kaur I, Tsering T, Erzingatzian A Sci Adv. 2025; 11(9):eads5249.

PMID: 40009680 PMC: 11864201. DOI: 10.1126/sciadv.ads5249.


Glycopolypeptide Coordinated Nanovaccine: Fabrication, Characterization, and Antitumor Immune Response.

Song Y, Teng L, Chen Y, Dong C Chem Bio Eng. 2025; 1(7):633-646.

PMID: 39974696 PMC: 11835264. DOI: 10.1021/cbe.4c00083.


Enhanced tumor self-targeting of lemon-derived extracellular vesicles by embedding homotypic cancer cell membranes for efficient drug delivery.

Yang L, Liang G, Cai B, Xu K, Zhao Y, Xie X J Nanobiotechnology. 2025; 23(1):74.

PMID: 39893448 PMC: 11786351. DOI: 10.1186/s12951-025-03161-z.


Plasma membrane-coated nanoparticles and membrane vesicles to orchestrate multimodal antitumor immunity.

Ito Y, Kasuya H, Kataoka M, Nakamura N, Yoshikawa T, Nakashima T J Immunother Cancer. 2025; 13(1).

PMID: 39864848 PMC: 11784344. DOI: 10.1136/jitc-2024-010005.


References
1.
Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

2.
Schoenborn J, Wilson C . Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007; 96:41-101. DOI: 10.1016/S0065-2776(07)96002-2. View

3.
Glinsky V, Glinsky G, Glinskii O, Huxley V, Turk J, Mossine V . Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 2003; 63(13):3805-11. View

4.
Reddy S, van der Vlies A, Simeoni E, Angeli V, Randolph G, ONeil C . Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007; 25(10):1159-64. DOI: 10.1038/nbt1332. View

5.
Mata-Haro V, Cekic C, Martin M, Chilton P, Casella C, Mitchell T . The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 2007; 316(5831):1628-32. DOI: 10.1126/science.1138963. View